ARS Pharmaceuticals' needle-free adrenaline nasal spray, EURneffy, recommended for approval by EMA for emergency allergic reaction treatment.

ARS Pharmaceuticals' needle-free adrenaline nasal spray, EURneffy, recommended for approval by the European Medicines Agency (EMA) for emergency treatment of allergic reactions. EURneffy is an alternative to EpiPen and other autoinjectors. The European Commission, expected to decide in Q3 2024, usually follows the EMA's recommendation. EURneffy is also under review by the U.S. FDA, with a decision due Oct.2.